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Background: To investigate the feasibility of dose escalation (86 Gy at 2 Gy/fraction) with intensity modulated
radiation therapy (IMRT) in intermediate-risk prostate cancer without androgen deprivation therapy.
Methods: Patients with histologically proven adenocarcinoma of the prostate, intermediate prognostic category,
were enrolled in this study. Early and late toxicity were scored according to the Cancer Therapy Evaluation Program,
Common Terminology Criteria for Adverse Events, Version 3.0. Treatment outcome was stated in terms of
biochemical failure, biopsy result and clinical failure.
Results: 39 patients with a median follow-up of 71 months were analyzed. No patient experienced G3 or G4 acute
gastrointestinal (GI) or genitourinary (GU) toxicity. G2 acute GI and GU toxicity were observed in 17 (44%) and 20
(51%) patients, respectively. Fourteen patients (36%) did not experience acute GI toxicity and 4 patients (10%) did
not experience acute GU toxicity. G2 late GI bleeding occurred in 7 of 39 patients (18%). Both G3 and G4 late GI
toxicity were seen only in one patient (2.5%). Two patients (5%) experienced G2 late GU toxicity, while G3 late GU
toxicity occurred in 3 patients (8%). The 5-year actuarial freedom from biochemical failure (FFBF) was 87%.
Thirty-four patients (87%) did not show biochemical relapse. Seventeen patients (44%) underwent biopsy two year
after radiotherapy; of these only two were non-negative and both did not show evidence of biochemical disease.
Conclusions: IMRT treatment of patients with localized intermediate-risk prostate cancer at high dose levels
without using androgen deprivation therapy (ADT) seems to give good disease control. Nevertheless, future trials
should aim at further decreasing toxicity by exploiting image guidance techniques and by reducing the dose
delivered at the interface between organs at risk and prostate.
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The use of dose escalation in radiation therapy, with
doses ranging from 74 to 80 Gy, has shown an improve-
ment in the outcome of prostate cancer when compared
with conventional doses, as reported in large retrospective
studies [1,2] and in some prospective randomized trials
[3-8]. Moreover, the dose–response curve of prostate* Correspondence: petrongari@ifo.it
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article, unless otherwise stated.cancer showed an optimal disease control in the region
of ultra-high dose levels (≥ 80 Gy) [9]. As a matter of
fact, dose escalation has improved distant metastasis-
free survival (DMFS) and cancer-specific survival (CSS)
[10-13]. However, the use of three-dimensional con-
formal radiation therapy (3D-CRT) for dose escalation
is limited by side effects [3-7,14]; while intensity-modulated
radiation therapy (IMRT) generally decreases treatment-
related morbidity by producing steeper dose-gradients
[13,15-17]. At MSKCC [17,18] the feasibility of dose
escalation from 81 Gy to 86.4 Gy at 1.8 Gy/fraction intral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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Androgen Deprivation Therapy (ADT) has been investi-
gated, suggesting that ultra-high dose regimen is well toler-
ated and reporting an excellent biochemical control.
However the role and the optimal duration of ADT with
dose escalated radiation therapy still remains controversial.
The aim of our paper is to report the outcome of a
dose-escalation study with an ultra-high dose of 86 Gy
at 2 Gy/fraction with IMRT technique in intermediate-
risk prostate cancer patients, without the use of ADT, in
terms of toxicity and biochemical control.
Methods
This is a single institution prospective phase II study ap-
proved by Regina Elena National Cancer Institute, Ethical
Committee. Patients enrolled in the study belonged to the
intermediate prognostic category according to the National
Comprehensive Cancer Network classification system
(www.nccn.com) which included patients with stage
T2b-T2c tumors, and PSA >10 ng/ml but ≤ 20 ng/ml,
and Gleason score 7. The clinical characteristics of pa-
tients and tumors are shown in Table 1.
Inclusion criteria were: 1) age <80 years; 2) histological
proof of prostate adenocarcinoma at intermediate risk;
3) risk of lymph node involvement < 15%, according to
Roach formula, or absence of adenopathy assessed byTable 1 Clinical characteristics of patients and tumor
staging
Age (years)
Median (range) 72 (53–77)
Follow-up (mos)








7 (3 + 4) 20 (51.3%)








10–19.9 2 (5%)CT and/or MRI; 4) WHO performance status < 2; 5) no
previous pelvic radiotherapy; 6) no previous prostate sur-
gery; 7) no previous hormonal therapy; 8) no previous ma-
lignant tumors, with the exception of adequately treated
cutaneous carcinomas; 9) declared availability to comply
with the planned follow-up examinations; 10) written in-
formed consent. All patients were free of ADT treatment.
Written informed consent was signed by all patients.
Patients underwent a CT simulation in the prone pos-
ition by using a customized device for immobilization.
A CT scan was performed at 5 mm intervals from L4/L5
to 5 cm below the ischial tuberosities. Patients were
asked to void the rectum before simulation and before
each treatment session, also with the use of glycerine
suppositories or enemas. The bladder had to be taken at
middle filling by voiding it 1.5 hours before simulation
and daily before each treatment session. The acquired
images were then transferred to the Eclipse (v.8.9) treat-
ment planning system. The clinical target volume (CTV)
consisted of the prostate and entire seminal vesicles, the
planning target volume (PTV) was obtained by adding
1 cm margin in all directions except toward the rectum,
where the margin was reduced to 0.6 cm according to our
institutional policy [19]. The rectal and bladder walls
were contoured as critical normal structures, in par-
ticular, the rectum was outlined from the sigmoid flex-
ure to the anal margin. Patients were treated with a 15
MV five-field sliding window IMRT technique. The
beam arrangement was: posterior (0°), right posterior
oblique (75°), right anterior oblique (135°), left anterior
oblique (225°) and left posterior oblique (285°). Plans
were optimized to give at least 95% and 90% of the pre-
scribed dose to CTV and PTV, respectively. The max-
imum dose heterogeneity within the PTV was set at
17% (from 90% to 107%). No constraints were applied
to the overlapping volume between the PTV and rec-
tum, which was treated as PTV. Dose-volume con-
straints were set for rectal and bladder walls and
femoral heads. Dose-volume constraints were: max-
imum 70 Gy, 50 Gy and 40 Gy to 30%, 50% and 60% of
the rectal wall volume, respectively, maximum 70 Gy
and 50 Gy to 50% and 70% of the bladder wall volume,
respectively, and maximum 55 Gy to 70% of the fem-
oral heads. The normal tissue planning limits were
based on our prior experience and on previously pub-
lished studies [20-25]. Dose-volume histograms were
recorded for all patients. Patients were treated with
Varian 2100 linear accelerators (Varian Associates, Palo
Alto, CA) equipped with 120-leaf multi-leaf collima-
tors. The accuracy of the set-up was monitored daily by
verifying the position of the isocenter comparing skel-
etal landmarks on orthogonal portal images acquired
with an electronic portal imaging device (EPID) to the
digitally reconstructed radiography (DRRs).
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The primary endpoint of our study was gastrointestinal
(GI) and genitourinary (GU) toxicity. Early and late tox-
icity data were scored according to the Cancer Therapy
Evaluation Program, Common Terminology Criteria for
Adverse Events, Version 3.0 [26]. Grade 1–4: Grade 1
(mild) - asymptomatic or mild symptoms requiring only
clinical or diagnostic observation; Grade 2 (moderate) -
minimal, local or noninvasive intervention indicated;
Grade 3 (severe) - severe or medically significant but not
immediately life-threatening requiring hospitalization,
prolonging hospitalization or affecting activities of daily
living; Grade 4- life-threatening consequences requiring
urgent intervention. Acute side effects occurred during
the course of radiation or within 90 days of its completion.
Late toxicity was defined as rectal or urinary symptoms
occurring or persisting 6 months or more after completing
radiotherapy. The secondary endpoints were biochemical
failure, biopsy result and clinical failure. The freedom from
biochemical failure (FFBF) was defined as the time interval
from the first day of radiotherapy to the biochemical
relapse, the scores are according to the most recent
Phoenix definition of nadir PSA +2 ng/ml [27]. The
histological diagnosis of the prostate biopsy at 2-years
post-radiotherapy was classified as positive (prostatic ade-
nocarcinoma without typical radiation-induced changes),
negative (no evidence of carcinoma) or indeterminate
(severe treatment effects).Baseline and follow-up
All patients were prostate adenocarcinoma pre-treatment
biopsy proven. Baseline staging was assessed by initial
PSA (iPSA) levels, digital rectal examination (DRE),
transrectal ultrasound images, abdomino-pelvic CT,
chest RX/CT and bone scan. At baseline, patients were
asked to answer questions about their urinary symp-
toms according to the International Prostate Symptoms
Score (IPSS) questionnaire [28]. Patients were moni-
tored weekly during the course of radiotherapy, after 2
and 6 months from the end of the treatment, and then
every six months until the second year of follow-up.
Afterwards patients were monitored annually. PSA
evaluation and DRE were performed at each follow-up
visit and a report was drafted, with special emphasis on
treatment-related morbidity, which recorded the worst
toxicity score for each patient. In case of an increased
PSA and/or suspected clinical local relapse (new or in-
creasing palpable prostate nodule) or distant failure
(bone pain, low extremity edema, unjustified dyspnea,
etc.), the usual diagnostic imaging procedures or pros-
tate biopsies were carried out. All patients underwent a
sextant prostate re-biopsy after at least 2 years after the
radiation treatment.Statistical analysis
For all measured endpoints, patients were censored at the
time of the specific event. Actuarial curves of the length of
time until late toxicity or biochemical failure were calcu-
lated by the Kaplan-Meier product-limit method. All times
were calculated from the first day of radiotherapy. Differ-
ences between dosimetric parameters between groups
were evaluated by a Mann–Whitney test.
Results
Patients and dosimetry
From January 2005 to April 2010 39 patients with histo-
logically proven adenocarcinoma of the prostate were en-
rolled in an IMRT dose escalation protocol with a total
dose of 86 Gy in 43 fractions. The rate of accrual was lim-
ited by the inclusion criteria of freedom from ADT. The
median follow-up for the cohort was 71 months (range
32.8-93.6 months) and the median age was 71.5 years
(range 52.5-77.4 yrs). On average, 99.9% (standard devi-
ation 0.1%) of the PTV volume received at least 77.5 Gy
(V100), and 95% of the PTV volume (D95) received an
average dose of 82.7 Gy (standard deviation: 1.0 Gy). The
dose volume constraints were fulfilled in every patient, the
mean percentage volume of rectum receiving 40 Gy, 50 Gy
and 70 Gy being equal to 44.0% (±8.0), 34.9% (± 6.3) and
19.9% (± 4.7), respectively, and the mean percentage
volume of bladder receiving 50 Gy and 70 Gy equal to
32.7% (±11.9) and 19.2% (± 8.2), respectively. In particular
the maximum and mean dose to the rectum were 87.5 Gy
(±1.2) and 42.5 Gy (±4.8), respectively; while the dose
received by more than 1 and 5 cc of the rectum were
85.1 Gy (±1.3) and 79.1 Gy (±4.3), respectively.
Toxicity
The IPSS questionnaire at baseline resulted in 36/39 (92%)
of asymptomatic or low symptomatic patients (IPSS
score ≤ 7), 3/39 (8%) moderate symptomatic (IPSS score
8–19), no patient was severely symptomatic (IPSS score
20–35). In our cohort, the acute side effects of radiother-
apy were moderate and transient. No patient experienced
G3 or G4 acute gastrointestinal (GI) or genitourinary
(GU) toxicity. G2 acute GI and GU toxicity were observed
in 17 (44%) and 20 (51%) patients, respectively (Figure 1).
Fourteen patients (36%) did not experience acute GI and 4
patients (10%) did not experience acute GU toxicity. G2
late GI bleeding occurred in 7 of 39 patients (18%). Both
G3 and G4 late GI toxicity were seen only in one patient
(2.5%); in the first case G3 late GI toxicity was character-
ized by persistent bleeding treated with 4 sessions of laser
coagulation, in the second case the G4 late GI toxicity was
a fistula which required packing a temporary colostomy.
Two patients (5%) experienced G2 late GU toxicity, while
G3 late GU toxicity characterized by urethral stricture
occurred in 3 patients (8%), two of whom had undergone
Figure 1 Incidence (% of patients) of acute and late gastrointestinal (GI) and genitourinary (GU) toxicity.
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before radiotherapy; no patient experienced G4 late GU
toxicity (Figure 1). The actuarial analysis of ≥G2 late GI
and GU complications is reported in Figure 2. The 5-year
actuarial incidence of ≥G2 late GI and GU complications
was 21.0% (std error 6.6%) and 12.8% (std error 5.4%),
respectively. In Figure 3 mean dose volume histograms
of the volume of rectum enclosed in the PTV are shown: a
statistically significant difference was found between pa-
tients who did and did not experience late ≥2 GI toxicity
(p < 0.0001 Mann–Whitney test).
Biochemical control rates and biopsies
The 5-year actuarial FFBF after ultra-high IMRT dose of
86 Gy at 2 Gy/fraction was 87% (standard error 6%), with-
out the use of ADT, as shown in Figure 4. Five patients
(13%) had a biochemical failure, one of these presentedFigure 2 Actuarial incidence of ≥G2 late GI and GU toxicity.also a local relapse and two patients presented also
distance metastasis, while 34 (87%) did not show evidence
of biochemical disease. Out of 39 patients, 22 patients re-
fused undergoing a biopsy at 2-years post-radiotherapy.
Out of 17 patients who underwent re-biopsy, 15 biopsies
(88%) resulted completely negative, 1 (6%) positive and 1
(6%) indeterminate, but both the last two patients did not
show evidence of biochemical disease.
Discussion
Our study represents the first prospective trial reporting
results of the highest dose escalation using doses of 86 Gy
at 2 Gy/fraction, for the IMRT treatment of patients
with localized intermediate-risk prostate cancer without
ADT. Out of 39, 7 patients (18%) reported G2 late GI
toxicity, one patient (2.5%) reported G3 late GI toxicity
and one patient (2.5%) reported G4 late GI toxicity. In
Figure 3 Mean dose volume histograms of the volume of rectum enclosed in the PTV for patients who did and did not experience late
GI toxicity.
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than expected from cases treated at our Institute with
IMRT at doses of 80 Gy and from the literature [15-18].
However, the observed actuarial ≥G2 late GI toxicity
(21%) was lower to that found in the study RTOG 9406
conducted by Michalski et al. [29] reporting a rate of ≥G2
GI complication ranging from 30% to 33% for 24 months
at dose level V (78 Gy) but higher than that (4%) reported
by Cahlon et al. [17]. The higher observed ≥G2 late GI
toxicity might be due to the lack of specific dose con-
straints for rectum volume within the PTV and to the factFigure 4 Freedom from biochemical failure survival.that also seminals vesicles received the full treatment dose.
In fact a statistically significant correlation was observed
between dose volume histograms of the volume of rectum
enclosed in the PTV and ≥G2 late GI toxicity. It is worth
noting that patients were enrolled in this study before the
publication of Quantec [30], where it is stated that “Redu-
cing the V75 by just 5% from 15% to 10% has a significant
impact in the predicted complication probability …” but
“the proposed dose–volume constraints might be un-
achievable … but every effort should be made to be as
close as possible to the constraints especially in the high
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the PTV, such as CBCT and/or markers for IGRT, could
further reduce the incidence of rectal toxicity [31,32],
considering that the prostate and the anterior rectal
wall, i.e. the area most susceptible to receive an high
dose, cannot be seen using EPID images only. In ran-
domized dose-escalation trials employing 3D-CRT the
incidence of ≥G2 late GI toxicity ranged between 17%
and 32% [3-7]. This GI toxicity are similar to our re-
sults, even if in our trial higher doses were delivered.
Moreover, pre-radiotherapy ADT has been reported as
a protective factor for GI late toxicity due to the expected
reduction of PTV volume [33].
No patients experienced G4 late GU toxicity and three
patients (8%) developed G3 late GU toxicity, two of
which were previously treated for urethral stricture. The
observed 5-year incidence of ≥G2 late GU toxicity was
12.8%, which seems comparable to the 5-year actuarial
risk (of 16%) reported by Cahlon et al. [17], and to the
3-year actuarial risk of 19% G2 late GU reported by Fon-
teyene et al., with doses between 72 Gy and 78 Gy [16].
However, comparisons of patients across study cohorts are
difficult and should be interpreted with caution. In par-
ticular, the role of hormone therapy in the setting of dose
escalation could introduce some bias, thus confounding
the analysis, which needs to be evaluated in a randomized
trial. The observed five years FFBF of 87%, according to
the Phoenix definition, is comparable with the results of
85% reported by Cahlon et al. [17], using a total dose of
86.4 Gy (1.8 cGy/fraction) in combination with neoadju-
vant or concurrent ADT. The true role of androgen
deprivation in dose escalation schedules in patients with
intermediate prognosis risk is currently unknown, the fact
that hormonal therapy was not used in this study did not
seem to impact on the outcome, even though, more pa-
tients and a longer follow up are needed to clearly state
the role of ADT. Cell killing by hormone-therapy could
reduce the tumor burden, enhancing local control, and
maybe decreasing the rate of distant metastases [34]. Eade
et al. [9] suggested that the use of doses >80 Gy for local-
ized prostate cancer results in better local control and less
distant failures when compared to doses <80 Gy, analyzing
a cohort of patients free from ADT. In this report, the au-
thors observed a reduced risk of biochemical recurrence
of 2.2% at 8 years for the addition of each Gy over 80 Gy
and concluded that the plateau on the dose–response
curve for prostate cancer lies well above 80 Gy. Also, feasi-
bility studies of single Institutions and some randomized
trials of dose escalation showed improved results in the
treatment of localized prostate cancer [1-8]; analyzing the
effects of increased doses between prognostic categories,
the best results are observed in the intermediate risk
[3-9,15,34-36]. Even though, with a larger number of en-
rolled patients a multivariate analysis could better clarifythe results observed, we believe that the current series
demonstrates the advantage in terms of disease control of
using ultra-high doses in the treatment of intermediate
risk prostate cancer while the incidence of toxicity ob-
served could be lowered by applying stricter requirements
on the dose volume constraints at the interface of the rec-
tum with the posterior portion of the prostate gland and
introducing a more advanced imaging protocol, i.e. cone
beam CT imaging. Moreover, authors are aware that qual-
ity of life questionnaires to investigate treatment effects as
reported by patients could have added information to the
overall rating of treatment results; for this reason, since
then, great effort has been made to introduce in our policy
also this additional tool of evaluation.
Conclusion
Our results proved to be good in terms of FFBF without
using ADT in intermediate-risk prostate cancer patients.
Although a longer follow up and more patients are needed
to assert that ultra-high dose escalation using IMRT could
be a viable alternative to lower doses plus ADT, though
manifesting an increase of ≥G2 late GI rate, the data re-
ported in this study seem promising. Finally, even if the in-
clusion criteria of freedom from ADT is a very limiting
factor for the accrual rate in the intermediate risk patient
cohort because ADT is often a standard therapeutic strat-
egy, we believe that only a randomized study can accur-
ately compare outcomes between different doses in dose
escalation schedules.
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